Get started
Processa Pharmaceuticals, Inc.Processa Pharmaceuticals, Inc.Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

PCSA chart


Full chart

PCSA upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪3.10 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−5.0176 USD
Net income (FY)
‪−11.12 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪2.90 M‬
Beta (1Y)
1.26

Employees


Employees (FY)
13
Change (1Y)
−2 −13.33%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−855.50 K‬ USD

About Processa Pharmaceuticals, Inc.


Sector
Health Technology
CEO
George K. Ng
Headquarters
Hanover
Website
processapharmaceuticals.com
Founded
2011
FIGI
BBG003MN5ZP8
Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its main product candidate is PCS499, which is intended for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on March 29, 2011 and is headquartered in Hanover, MD.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

PCSA news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of PCSA is 0.8710 USD — it has decreased by −1.51% in the past 24 hours. Watch Processa Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Processa Pharmaceuticals, Inc. stocks are traded under the ticker PCSA.
PCSA stock has fallen by −22.48% compared to the previous week, the month change is a −4.86% fall, over the last year Processa Pharmaceuticals, Inc. has showed a −88.23% decrease.
We've gathered analysts' opinions on Processa Pharmaceuticals, Inc. future price: according to them, PCSA price has a max estimate of 6.00 USD and a min estimate of 6.00 USD. Watch PCSA chart and read a more detailed Processa Pharmaceuticals, Inc. stock forecast: see what analysts think of Processa Pharmaceuticals, Inc. and suggest that you do with its stocks.
PCSA reached its all-time high on Nov 22, 2013 with the price of 7,847.4451 USD, and its all-time low was 0.8442 USD and was reached on Dec 20, 2024. View more price dynamics on PCSA chart.
See other stocks reaching their highest and lowest prices.
PCSA stock is 7.80% volatile and has beta coefficient of 1.26. Track Processa Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Processa Pharmaceuticals, Inc. there?
Today Processa Pharmaceuticals, Inc. has the market capitalization of ‪3.10 M‬, it has decreased by −6.17% over the last week.
Yes, you can track Processa Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Processa Pharmaceuticals, Inc. is going to release the next earnings report on Mar 27, 2025. Keep track of upcoming events with our Earnings Calendar.
PCSA earnings for the last quarter are −1.03 USD per share, whereas the estimation was −1.00 USD resulting in a −3.00% surprise. The estimated earnings for the next quarter are −0.92 USD per share. See more details about Processa Pharmaceuticals, Inc. earnings.
PCSA net income for the last quarter is ‪−3.38 M‬ USD, while the quarter before that showed ‪−3.01 M‬ USD of net income which accounts for −12.44% change. Track more Processa Pharmaceuticals, Inc. financial stats to get the full picture.
No, PCSA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 13.00 employees. See our rating of the largest employees — is Processa Pharmaceuticals, Inc. on this list?
Like other stocks, PCSA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Processa Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Processa Pharmaceuticals, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Processa Pharmaceuticals, Inc. stock shows the sell signal. See more of Processa Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.